Free Trial

Iradimed Q1 2023 Earnings Report

Iradimed logo
$60.33 +1.16 (+1.96%)
As of 04:00 PM Eastern

Iradimed EPS Results

Actual EPS
$0.27
Consensus EPS
$0.25
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Iradimed Revenue Results

Actual Revenue
$15.48 million
Expected Revenue
$14.76 million
Beat/Miss
Beat by +$720.00 thousand
YoY Revenue Growth
N/A

Iradimed Announcement Details

Quarter
Q1 2023
Time
N/A

Iradimed Earnings Headlines

IRADIMED Reports Record Revenues for Q4 2024 and Full-Year 2024
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Iradimed (IRMD) Gets a Buy from Lake Street
Iradimed Reports Growth In Q4, FY Preliminary Revenues
iRadimed reports preliminary Q4 revenue $19.2M-$19.4M
See More Iradimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email.

About Iradimed

Iradimed (NASDAQ:IRMD) Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

View Iradimed Profile

More Earnings Resources from MarketBeat